As for the potential role of claudins in colorectal cancer, anti-claudin-1 antibodies specifically bind claudin-1 on the membrane of tumor cells and inhibit tumor progression in vivo and in vitro, indicating that claudin-1 may be a therapeutic target for colorectal cancer, especially for subtypes with KRAS mutations and Wnt signaling activation (132). The gene discussed is KRAS; the disease is neoplasm.